Rift Valley Fever – A Comprehensive Medical Guide

Overview

Rift Valley fever (RVF) is a viral zoonotic disease caused by the Rift Valley fever virus (RVFV), a member of the Phlebovirus genus in the family Phenuiviridae. The virus is primarily transmitted to humans through the bite of infected mosquitoes (most commonly Aedes and Culex species) or by direct contact with the blood, organs, or bodily fluids of infected animals (especially sheep, goats, cattle, and camels).

RVF was first identified in the Rift Valley of Kenya in 1931 and has since caused periodic outbreaks in Africa, the Arabian Peninsula, and, more recently, isolated cases in Europe linked to infected animal imports. The World Health Organization (WHO) estimates that between 30 000 and 50 000 human cases have been reported since the virus was discovered, with a case‑fatality rate of 0.5–2 % for the mild form and up to 50 % for the severe hemorrhagic form.¹

The disease can affect anyone exposed to infected vectors or animals, but certain groups are at higher risk:

• Farm workers, veterinarians, and slaughterhouse employees
• People living in rural, agricultural communities where livestock are kept
• Travelers or aid workers deployed to outbreak regions

Symptoms

RVF has a broad clinical spectrum ranging from an asymptomatic infection to a severe, life‑threatening illness. Symptoms usually appear 2–6 days after exposure (incubation period).

Mild (or “flu‑like”) form

• Fever – sudden onset of high temperature (≥38.5 °C).
• Headache – often throbbing and persistent.
• Myalgia – muscle aches, especially in the calves and back.
• Fatigue – which may last weeks.
• Joint pain – can mimic arthritis.
• Retro‑orbital pain – pain behind the eyes.
• Nausea & vomiting – sometimes accompanied by loss of appetite.

Severe forms

• Hemorrhagic fever – bruising, bleeding from gums, nose, gastrointestinal tract, or vaginal bleeding.
• Encephalitis – confusion, seizures, focal neurological deficits, and sometimes coma.
• Ocular disease – retinal hemorrhage, uveitis, or loss of vision (reported in up to 10 % of hospitalized patients).²
• Acute renal failure – reduced urine output, swelling, and elevated creatinine.
• Hepatitis – jaundice, markedly elevated liver enzymes (AST/ALT >300 U/L), and abdominal pain.

Causes and Risk Factors

How the virus spreads

1. Mosquito bite – Aedes mosquitoes can transmit the virus vertically (from infected female to eggs), allowing the virus to persist in dry, dormant eggs for years.
2. Direct animal contact – Handling or butchering infected livestock, especially during birthing or abortion events, releases high viral loads.
3. Blood transfusion or organ transplantation – Rare but documented cases.
4. Aerosol exposure – In laboratory settings or during slaughtering, virus‑laden aerosols can be inhaled.

Key risk factors

• Living or working in endemic regions (Sub‑Saharan Africa, Saudi Arabia, Yemen).
• Seasonal rain floods that create abundant mosquito breeding sites.
• Occupations with frequent animal contact (farmers, veterinarians, abattoir workers).
• Lack of personal protective equipment (PPE) when handling sick animals.
• Travel to outbreak zones without proper mosquito protection.

Diagnosis

Because early symptoms mimic many other febrile illnesses (malaria, dengue, influenza), a high index of suspicion is essential, especially during an outbreak.

Clinical assessment

• Complete medical history focusing on recent travel, animal exposure, or mosquito bites.
• Physical exam looking for rash, bleeding, jaundice, or neurological signs.

Laboratory tests

1. Reverse transcription polymerase chain reaction (RT‑PCR) – Detects viral RNA in blood or serum; most sensitive during the first 5–7 days of illness.³
2. Enzyme‑linked immunosorbent assay (ELISA) – Measures IgM (recent infection) and IgG (past exposure) antibodies.
3. Virus isolation – Performed in biosafety level‑3 labs; used for research, not routine diagnosis.
4. Complete blood count (CBC) – May reveal leukopenia, thrombocytopenia, or anemia.
5. Liver function tests (LFTs) – Elevated AST/ALT, bilirubin in severe cases.
6. Renal panel & coagulation studies – To monitor for organ involvement.

Treatment Options

There is currently no specific antiviral therapy approved for RVF in humans. Treatment is largely supportive and focuses on managing complications.

Supportive care

• Fluid replacement – Intravenous isotonic solutions to maintain hydration and blood pressure.
• Fever control – Acetaminophen is preferred; avoid NSAIDs like ibuprofen if bleeding is a concern.
• Blood product transfusion – For severe hemorrhage or thrombocytopenia.
• Renal replacement therapy – Hemodialysis when acute kidney injury develops.
• Mechanical ventilation – For respiratory failure secondary to pulmonary edema or encephalitis.

Potential antiviral candidates (investigational)

Ribavirin has shown in‑vitro activity against RVFV, but clinical trials have produced mixed results and it is not routinely recommended. Trials of favipiravir and monoclonal antibodies are ongoing (Phase II) as of 2024.⁴

Lifestyle and adjunct measures

• Rest and adequate nutrition to support immune recovery.
• Monitoring of liver and kidney function through regular blood tests.
• Early physiotherapy if neurological deficits develop.

Living with Rift Valley Fever

Most patients recover fully within weeks, but some may experience prolonged fatigue, vision changes, or mild neurocognitive deficits. The following tips help ease daily life:

• Hydration – Aim for 2–3 L of water daily unless fluid restriction is advised by a clinician.
• Balanced diet – High‑protein foods (lean meat, legumes, dairy) aid tissue repair.
• Sleep hygiene – 7–9 hours of uninterrupted sleep each night.
• Vision monitoring – Prompt ophthalmology review if you notice blurring, flashes, or loss of field.
• Gradual return to activity – Begin with light walking; avoid heavy lifting or strenuous exercise until cleared.
• Psychological support – Counseling or support groups are valuable, especially after severe illness.

Prevention

Because there is no licensed human vaccine in most countries (a veterinary live‑attenuated vaccine exists for animals), prevention focuses on vector control and safe animal handling.

Personal protective measures

• Use insect repellent containing DEET (20‑30 %) or picaridin on exposed skin.
• Wear long‑sleeved shirts, long pants, and socks, especially at dusk and dawn.
• Sleep under insecticide‑treated bed nets in endemic areas.
• Apply permethrin to clothing and gear.
• When handling livestock, wear gloves, goggles, and waterproof gowns.
• Immediately wash any skin breaks with soap and water after animal contact.

Environmental control

• Eliminate standing water around homes (e.g., discard old tires, empty containers).
• Implement larviciding programs in flood‑prone regions.
• Coordinate with local veterinary services for animal vaccination campaigns.
• Restrict movement of livestock during known outbreaks.

Travel precautions

Travelers to endemic zones should consult a travel clinic 4–6 weeks before departure for up‑to‑date risk assessments and receive pre‑travel counseling on mosquito avoidance.

Complications

While most cases resolve without lasting effects, serious complications can arise, particularly in vulnerable populations (pregnant women, elderly, immunocompromised).

• Hemorrhagic syndrome – Can progress to shock and multi‑organ failure.
• Encephalitis – May leave permanent neurological deficits, such as memory loss or motor weakness.
• Ocular sequelae – Permanent visual impairment or blindness in up to 5 % of severe cases.
• Acute liver failure – Rare but carries a high mortality rate.
• Pregnancy loss – Infected pregnant women have an increased risk of miscarriage, stillbirth, or neonatal death.

When to Seek Emergency Care

Sources:

1. Mayo Clinic. “Rift Valley Fever.” Updated 2023. https://www.mayoclinic.org
2. Cleveland Clinic. “Ocular Manifestations of Rift Valley Fever.” 2022. https://my.clevelandclinic.org
3. World Health Organization. “Rift Valley fever – Fact sheet.” 2024. https://www.who.int
4. NIH National Institute of Allergy and Infectious Diseases. “Therapeutic candidates for Rift Valley fever.” 2024. https://www.niaid.nih.gov